Skip to content

Investigating the effects of Lavandula Tablet on the condition of headache in patients with migraine

Investigating the effects of treatment with Persian medicine (Lavandula Tablet) based herbal product, on the condition of headache in patients with migraine

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180103038199N18
Enrollment
52
Registered
2023-08-12
Start date
2023-08-06
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Intervention group: Patients with migraine receiving ?lavender tablet 500 mg three times a day for two months along with common treatments (Nortriptyline and propranolol). Intervention

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with Migraine Age between 20 to 60

Exclusion criteria

Exclusion criteria: Suffering from chronic diseases Suffering from diseases associated with weak immune system Using lavender products or unknown drugs in the last three months Abuse of drugs and substances History of seizures and head trauma Pregnant and lactating mothers

Design outcomes

Primary

MeasureTime frame
Change in pain intensity in migraine attacks. Timepoint: Every migraine attack. Method of measurement: VAS pain questionnaire.;Change in numbers of migraine attacks. Timepoint: Every migraine attack. Method of measurement: Checklist.;Change in pain duration in each migraine attack. Timepoint: Every migraine attack. Method of measurement: Checklist.

Secondary

MeasureTime frame
Changes in the impact of headache complications on quality of life. Timepoint: In every migraine attack. Method of measurement: HIT-6 questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Reza Askari

Mashhad University of Medical Sciences

askariv941@mums.ac.ir+98 51 3800 2264

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026